HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model
Paul Stockhammer, Cassandra S.L. Ho, Luca Hegedüs, Gábor Lotz, Eszter Molnár, Ágnes Bánkfalvi, Thomas Herold, Stavros Kalbourtzis, Till Ploenes, Wilfried Eberhardt, Martin Schüler, Clemens Aigner, Alexander Schramm, Balázs Hegedűs
Topics & Concepts
MedicineCancer researchAdenocarcinomaALK inhibitorCrizotinibAnaplastic lymphoma kinaseAcquired resistanceLung cancerInternal medicineCancerMalignant pleural effusionLung Cancer Treatments and MutationsHistone Deacetylase Inhibitors ResearchLung Cancer Research Studies